What does DR. DE WAELE S., ONCOLOGIE do?

DR. DE WAELE S., ONCOLOGIE is a specialist medical practice in Merelbeke-Melle. Private Limited, started on 3 January 2013, 1 establishment.

What is the address of DR. DE WAELE S., ONCOLOGIE?

The registered office of DR. DE WAELE S., ONCOLOGIE is located at Schaperstraat 47, 9820 Merelbeke-Melle.

Is DR. DE WAELE S., ONCOLOGIE still active?

Yes. According to the CBE (17 September 2026) DR. DE WAELE S., ONCOLOGIE is active, legal situation “Normale toestand”, started on 3 January 2013.

Is DR. DE WAELE S., ONCOLOGIE registered on Peppol?

Yes, DR. DE WAELE S., ONCOLOGIE is registered on the Peppol network with ID 0208:0502249766.

What is the enterprise number of DR. DE WAELE S., ONCOLOGIE?

The enterprise number of DR. DE WAELE S., ONCOLOGIE is BE0502249766.

When was DR. DE WAELE S., ONCOLOGIE founded?

DR. DE WAELE S., ONCOLOGIE was founded on 3 January 2013.

Who are the directors of DR. DE WAELE S., ONCOLOGIE?

According to the 2025 annual accounts, the directors of DR. DE WAELE S., ONCOLOGIE are: Stefanie De Waele.

Is DR. DE WAELE S., ONCOLOGIE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 3 January 2013; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DR. DE WAELE S., ONCOLOGIE make in 2025?

DR. DE WAELE S., ONCOLOGIE posted a profit after taxes of € 247,157 in financial year 2025.

What is the revenue of DR. DE WAELE S., ONCOLOGIE?

As a small company, DR. DE WAELE S., ONCOLOGIE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 377,471.

DR. DE WAELE S., ONCOLOGIE (Private Limited)

Dossier DR. DE WAELE S., ONCOLOGIE, printed on 17 September 2026 from databakkes.be/en/0502249766/dr-de-waele-s-oncologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

DR. DE WAELE S., ONCOLOGIE from Merelbeke-Melle, company number BE0502249766, closed financial year 2025 with a result of € 247,157 after tax. For that financial year DR. DE WAELE S., ONCOLOGIE recorded a gross margin of € 377,471 and equity of € 769,106. Compared with financial year 2024, the result moved from € 151,669 to € 247,157. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 20, 2026.

What it is worth Growing

€ 769,106

▲ 11% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 247,157

▲ 63% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 380,005

▼ 14% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 171,621 paid out

69 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 2,802

▲ € 2,222 vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 1,609

▼ 60% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 46,096

▲ 96% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 161,140 Gross margin 2022: € 161,140 First fiscal year in the series	€ 106,233 Gross margin 2023: € 106,233 ▼ 34% vs 2022 (€ 161,140) Unfavourable step	€ 260,255 Gross margin 2024: € 260,255 ▲ 145% vs 2023 (€ 106,233) Favourable step	€ 377,471 Gross margin 2025: € 377,471 ▲ 45% vs 2024 (€ 260,255) Favourable step	▲ 45%
Profit after taxes	€ 77,840 Profit after taxes 2022: € 77,840 First fiscal year in the series	€ 54,822 Profit after taxes 2023: € 54,822 ▼ 30% vs 2022 (€ 77,840) Unfavourable step	€ 151,669 Profit after taxes 2024: € 151,669 ▲ 177% vs 2023 (€ 54,822) Favourable step	€ 247,157 Profit after taxes 2025: € 247,157 ▲ 63% vs 2024 (€ 151,669) Favourable step	▲ 63%
Equity	€ 632,723 Equity 2022: € 632,723 First fiscal year in the series	€ 615,120 Equity 2023: € 615,120 ▼ 3% vs 2022 (€ 632,723) Unfavourable step	€ 693,570 Equity 2024: € 693,570 ▲ 13% vs 2023 (€ 615,120) Favourable step	€ 769,106 Equity 2025: € 769,106 ▲ 11% vs 2024 (€ 693,570) Favourable step	▲ 11%
Total debts	€ 61,492 Total debts 2022: € 61,492 First fiscal year in the series	€ 61,287 Total debts 2023: € 61,287 Unchanged (€ 61,492) Favourable step	€ 147,984 Total debts 2024: € 147,984 ▲ 141% vs 2023 (€ 61,287) Unfavourable step	€ 282,552 Total debts 2025: € 282,552 ▲ 91% vs 2024 (€ 147,984) Unfavourable step	▲ 91%
Cash	€ 153,774 Cash 2022: € 153,774 First fiscal year in the series	€ 207,145 Cash 2023: € 207,145 ▲ 35% vs 2022 (€ 153,774) Favourable step	€ 442,753 Cash 2024: € 442,753 ▲ 114% vs 2023 (€ 207,145) Favourable step	€ 380,005 Cash 2025: € 380,005 ▼ 14% vs 2024 (€ 442,753) Unfavourable step	▼ 14%
Retained profit	€ 601,523 Retained profit 2022: € 601,523 First fiscal year in the series	€ 583,920 Retained profit 2023: € 583,920 ▼ 3% vs 2022 (€ 601,523) Unfavourable step	€ 662,370 Retained profit 2024: € 662,370 ▲ 13% vs 2023 (€ 583,920) Favourable step	€ 737,906 Retained profit 2025: € 737,906 ▲ 11% vs 2024 (€ 662,370) Favourable step	▲ 11%
Dividend	€ 0 Dividend 2022: € 0 First fiscal year in the series	€ 72,426 Dividend 2023: € 72,426 Unchanged (€ 0) Unchanged	€ 73,219 Dividend 2024: € 73,219 ▲ 1% vs 2023 (€ 72,426) Unchanged	€ 171,621 Dividend 2025: € 171,621 ▲ 134% vs 2024 (€ 73,219) Unchanged	▲ 134%
Balance sheet total	€ 694,216 Balance sheet total 2022: € 694,216 First fiscal year in the series	€ 676,407 Balance sheet total 2023: € 676,407 ▼ 3% vs 2022 (€ 694,216) Unchanged	€ 841,554 Balance sheet total 2024: € 841,554 ▲ 24% vs 2023 (€ 676,407) Unchanged	€ 1,051,658 Balance sheet total 2025: € 1,051,658 ▲ 25% vs 2024 (€ 841,554) Unchanged	▲ 25%

Key figures of DR. DE WAELE S., ONCOLOGIE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to DR. DE WAELE S., ONCOLOGIE?

What happened at DR. DE WAELE S., ONCOLOGIE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 20, 2026 New annual accounts for financial year 2025: profit of € 247,157 (▲ 63% vs 2024). Source: NBB ↗
2021 Stefanie De Waele became a director. NBB
Feb 1, 2014 New establishment in Merelbeke-Melle. KBO
Jan 3, 2013 Start of the company according to the CBE. KBO

In short

From € 77,840 profit in 2022 to € 247,157 profit in 2025.

Paid € 231,839 in corporate taxes since 2022.

Best year ever: 2025, with € 247,157 profit.

Paid out € 317,266 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR. DE WAELE S., ONCOLOGIE? We notify you, reason included.

Follow DR. DE WAELE S., ONCOLOGIE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Stefanie De Waele

DR. DE WAELE S., ONCOLOGIE

Behind DR. DE WAELE S., ONCOLOGIE is Stefanie De Waele.

See the full network in the app

Directors

According to the 2025 annual accounts

Stefanie De Waele

Director

since 2021

Establishments

Establishment units

Physical locations of this company

Registered office

Schaperstraat 47

9820 Merelbeke-Melle

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0502.249.766
VAT number: BE 0502.249.766
Registered office: Schaperstraat 47, 9820 Merelbeke-Melle
Names & denominations: DR. DE WAELE S., ONCOLOGIE
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 3 January 2013
Peppol: Active · Active since 24 Nov 2023
Contact: [email protected] 0476790039
Activities · NACE: Activiteiten van medisch specialisten

View on CBE Public ↗ Annual accounts (NBB) ↗